SELECT PUBLICATIONS

Atkins MB et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18. Abstract

Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: Results from the First National Wilms’ Tumor Study. Cancer 1978;41:1937-48. Abstract

Carroll PR et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet 1987;26:253-9. Abstract

George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349:419-21. No abstract available

Hoffman MA et al. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-27. Abstract

Hudes G et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon- alpha (IFN) or the combination of TEMSR + IFN in the treatment of firstline, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCO 2006;Abstract LBA4.

Rini BI et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proc ASCO 2006;Abstract 4522.

 

 

 

 

 

 

 

 

 

Home

Editor’s Note:
Renal cell fireworks

Interviews
Nicholas J Vogelzang, MD
- Select publications

Ronald M Bukowski, MD
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office